Mergetpa

Overview

Mergetpa is a reversible Arg-carboxypeptidase inhibitor with high affinity. Mergetpa reduces B1R . Mergetpa blocks the overexpression of IL-1β protein and mRNA in glucose-fed rats. Mergetpa significantly increases the expression of IL-1β protein in the renal cortex. Mergetpa is used to block the conversion of kinins and B2 receptor antagonists into metabolites lacking the C-terminal arginine. Mergetpa inhibits the time-dependent enhancement of the response of isolated rabbit aorta to bradykinin. Mergetpa preserves the chemotactic activity of full-length SDF-1α on cells. Mergetpa reverses hyperglycemia, excessive weight gain, elevated levels of oxidative stress markers and overexpression of inflammatory markers in glucose-fed rats.

Application

Products | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Carboxypeptidase | Products > Signaling Pathways > Bradykinin Receptor | Products > Signaling Pathways > Interleukin Related

Product Information

• Catalog No.: HY-W704574
• CAS No.: 77102-28-4
• Molecular Formula: C7H15N3O2S2
• Molecular Weight: 237.34
• Purity: 95.55%
• Storage: 4°C, stored under nitrogen, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
• Availability: In-stock

Source

Original product source